Table 4.
Prospective published studies of local consolidative therapy in OM NSCLC
| Author | Study design | Patients (n) | Sites (n) | Intervention | Med FU (months) | Inclusion | Median outcomes in months |
| Gomez et al19 (NSCLC) |
RCT-II CRT arm No CRT |
25 24 |
≤3 | LCT+MT vs MT/O alone | 38.8 | Synchronous* | PFS 14.4 vs 4.4 OS 41.2 vs 17 |
| Iyengar et al20 (NSCLC) |
RCT-II | 14 15 |
≤5 | SABR+MT vs MT alone | 9.6 | Synchronous | PFS 9.7 vs 3.5 |
| Palma et al31 (various primaries) |
RCT-II | 66 33 |
≤5 | SABR+SOC vs SOC alone | 26 | Synchronous or metachronous | OS 41 vs 28 |
| Sutera et al29 (various primaries) |
Phase II | 147 (lung-32) |
≤5 | SABR | 41.3 | Synchronous or metachronous | OS 42.3 (lung OS—26.8) |
| De Ruysscher et al32 (NSCLC) | Phase II | 40 | ≤5 | SABR | 27.7 | Synchronous | OS—13.5 |
| Petty et al30 (NSCLC) | Phase II | 29 | ≤5 | SBRT | 24.2 | Synchronous | OS—28.4 PFS—11.2 |
| Collen et al33 (NSCLC) | Phase II | 26 | ≤5 | SBRT | 16.4 | OS—23 PFS—11.2 |
|
| Arrieta et al34 (NSCLC) | Phase II | 37 | ≤5 | RCT | 32.5 | Synchronous* | OS—not reached PFS—23.5 |
*Includes oncogene mutation-positive patients.
LAT, local ablative therapy; LCRT, local consolidation radiation therapy; NSCLC, non-small cell lung cancer; OM, oligometastases; OS, overall survival; PFS, progression-free survival; RCT, randomised controlled trial; SABR, stereotactic ablative radiotherapy; SBRT, stereotactic body radiation therapy; SMT, standard maintenance therapy; SOC, standard of care; TNBC, triple-negative breast cancer.